[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336959-105":59,"doc-detail-336959-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","a-framework-for-target-discovery-in-rare-cancers","A framework for target discovery in rare cancers","","Large-scale functional genetic screens have identified many cancer dependencies, yet rare cancers remain underrepresented, leaving the dependency landscape unclear. This study used genome-scale CRISPR knockout screens in a TFE3 translocation renal cell carcinoma model to reveal novel, tRCC-selective vulnerabilities tied to mitochondrial biogenesis, oxidative metabolism, and kidney lineage specification. To generalize where models are limited, machine learning inferred gene dependencies from transcriptional profiles, predicting and validating MCL1 as an ASPS dependency distinct from tRCC. The framework was further applied across TCGA and multiple rare cancer cohorts to nominate potentially actionable vulnerabilities, including in poorly characterized cancer types.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-framework-for-target-discovery-in-rare-cancers/336959/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-framework-for-target-discovery-in-rare-cancers/336959.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why are rare cancers poorly represented in existing functional genetic screening efforts?","Question",{"text":112,"@type":113},"Because large-scale functional genetic screens under-sample rare cancer types, leaving their dependency landscape obscure. Limited molecular profiles and few robust cellular models further restrict comprehensive discovery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were gene dependencies identified for a rare cancer with limited experimental models?",{"text":117,"@type":113},"The study first performed genome-scale CRISPR knockout screens in an exemplar rare cancer, then trained machine learning to infer gene dependencies from transcriptional profiles for other rare cancers where models are not readily available.",{"name":119,"@type":110,"acceptedAnswer":120},"What dependency difference was discovered between ASPS and tRCC?",{"text":121,"@type":113},"The model and subsequent validation indicated that MCL1 is a dependency in alveolar soft part sarcoma (ASPS) but not in TFE3 translocation renal cell carcinoma (tRCC).",{"name":123,"@type":110,"acceptedAnswer":124},"How were the predictions extended beyond a single rare cancer type?",{"text":125,"@type":113},"The approach was applied to tumors in TCGA and to multiple additional rare cancer cohorts, nominating potentially actionable vulnerabilities across diverse, including poorly characterized, cancer types and lineages.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336959,1790615772,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","bioRxiv preprint doi: [https://doi.org/10.1101/2024.10.24.620074](https://doi.org/10.1101/2024.10.24.620074); this version posted October 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC-ND 4.0 International license.  \n1 Title  \n2 A framework for target discovery in rare cancers  \n3 Authors  \n4 Bingchen Li1 ,╫, Ananthan Sadagopan1,╫, Jiao Li1, Yuqianxun Wu1, Yantong Cui1, Prathyusha Konda1, 5 Cary N. Weiss1,2, Toni K. Choueiri1,3,4, John G. Doench5, Srinivas R. Viswanathan1,3,4,5*  \n6 Affiliations  \n7 1 Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.  \n8 2 Department of Pediatric Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.  \n9 3 Department of Medicine, Harvard Medical School; Boston, MA 02215, USA.  \n10 4 Department of Medicine, Brigham and Women’s Hospital; Boston, MA 02215, USA.  \n11 5 Broad Institute of MIT and Harvard; Cambridge, MA 02142, USA.  \n12 ╫Authors contributed equally.  \n13 *To whom correspondence should be addressed: [srinivas.viswanathan@dfci.harvard.edu](srinivas.viswanathan@dfci.harvard.edu) (S.R.V) 14  \nbioRxiv preprint doi: [https://doi.org/10.1101/2024.10.24.620074](https://doi.org/10.1101/2024.10.24.620074); this version posted October 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC-ND 4.0 International license.  \n15 Abstract  \n16 While large-scale functional genetic screens have uncovered numerous cancer dependencies, rare cancers  \n17 are poorly represented in such efforts and the landscape of dependencies in many rare cancers remains  \n18 obscure. We performed genome-scale CRISPR knockout screens in an exemplar rare cancer, TFE3- 19 translocation renal cell carcinoma (tRCC), revealing previously unknown tRCC-selective dependencies in  \n20 pathways related to mitochondrial biogenesis, oxidative metabolism, and kidney lineage specification. To  \n21 generalize to other rare cancers in which experimental models may not be readily available, we employed  \n22 machine learning to infer gene dependencies in a tumor or cell line based on its transcriptional profile. By  \n23 applying dependency prediction to alveolar soft part sarcoma (ASPS), a distinct rare cancer also driven by TFE3  \n24 translocations, we discovered and validated that MCL1 represents a dependency in ASPS but not tRCC.  \n25 Finally, we applied our model to predict gene dependencies in tumors from the TCGA (11,373 tumors; 28  \n26 lineages) and multiple additional rare cancers (958 tumors across 16 types, including 13 distinct subtypes of  \n27 kidney cancer), nominating potentially actionable vulnerabilities in several poorly-characterized cancer types.  \n28 Our results couple unbiased functional genetic screening with a predictive model to establish a landscape of  \n29 candidate vulnerabilities across cancers, including several rare cancers currently lacking in potential targets.  \n30 Main Text  \n31 Introduction  \n32 A cornerstone of precision oncology is the matching of therapies to specific cancers based on  \n33 predictive molecular features. Recent advances in the molecular classification of cancer coupled with  \n34 advances in genome-scale functional genetic screening have enabled the discovery of multiple biomarker- 35 drug pairs that have proven clinically effective in specific cancer subtypes (1–9) . Still, limited molecular  \n36 profiles of rare cancer types and a paucity of robust cellular models for many of these cancers remain barriers  \n37 to fully realizing the ideal of precision oncology; this is in spite of the fact that many rare cancers have  \n38 homogeneous genomic landscapes with singular driver alterations that may be directl","cbCaivJhqbuPtIRN","https://ap.wps.com/l/cbCaivJhqbuPtIRN","pdf",5080273,39,"English","# Abstract\n## Introduction","[{\"question\":\"Why are rare cancers poorly represented in existing functional genetic screening efforts?\",\"answer\":\"Because large-scale functional genetic screens under-sample rare cancer types, leaving their dependency landscape obscure. Limited molecular profiles and few robust cellular models further restrict comprehensive discovery.\"},{\"question\":\"How were gene dependencies identified for a rare cancer with limited experimental models?\",\"answer\":\"The study first performed genome-scale CRISPR knockout screens in an exemplar rare cancer, then trained machine learning to infer gene dependencies from transcriptional profiles for other rare cancers where models are not readily available.\"},{\"question\":\"What dependency difference was discovered between ASPS and tRCC?\",\"answer\":\"The model and subsequent validation indicated that MCL1 is a dependency in alveolar soft part sarcoma (ASPS) but not in TFE3 translocation renal cell carcinoma (tRCC).\"},{\"question\":\"How were the predictions extended beyond a single rare cancer type?\",\"answer\":\"The approach was applied to tumors in TCGA and to multiple additional rare cancer cohorts, nominating potentially actionable vulnerabilities across diverse, including poorly characterized, cancer types and lineages.\"}]","A framework for target discovery in rare cancers | PDF",1790017205,98,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69411b7ac8b84150c858d29dfa7867c8.webp",983,1272,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd26e41f7301bc1665f50fa8c1c64097.webp",982,1270,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b02ad4538e9d86b45d66734793b9b541.webp",981,1269,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a118e6e08e5bbfbc24e58542920af99.webp",980,1268]